Previous 10 | Next 10 |
Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause The First Clinical Study Using the Novel Segmented Intravaginal Ring (IVR) Technology Validates its Potential to Provide a Versatile Convenient Drug Delivery Solutio...
vTv Therapeutics (VTVT) +28% on licensing agreement with Cantex.Adial Pharmaceuticals (ADIL) +22%.Bio-Path Holdings (BPTH) +22% as USPTO grants a new patent.Beyond Air (XAIR) +12%.Sanderson Farms (SAFM) +12% as it explores a potential sale.Idera Pharmaceuticals (IDRA) +11%.Insp...
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has been selected to deliver a company presentation at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021. ...
Daré Bioscience, Inc. (DARE) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer John Fair – Chief Strategy Officer Lisa Walters-Hoffert – Chief Financial Officer Conference Ca...
Dare Bioscience (DARE): Q1 GAAP EPS of -$0.16 beats by $0.09.Cash and cash equivalents: $7.7 million at March 31, 2021, compared to $4.7 million at December 31, 2020.Press Release For further details see: Dare Bioscience EPS beats by $0.09
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended March 31, 2021 and provided a company update. “The strong momentum of 2020 continued ...
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 13, 2021, to review its financi...
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that data from the Company’s postcoital test (PCT) clinical study of its novel investigational hormone-free monthly intravag...
Daré Bioscience (DARE) announces positive topline results from the DARE-BVFREE Phase 3 study of DARE-BV1, a thermosetting vaginal gel in women diagnosed with bacterial vaginosis. The study met its primary endpoint, demonstrating that as a primary therapeutic intervention a...
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that data from the DARE-BVFREE Phase 3 study of DARE-BV1, a thermosetting vaginal gel for the treatment of bacterial vaginosis...
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...